As this year’s American Society of Clinical Oncology meeting draws to a close, take a break from your flight, train ride, or Twitter binge for a look at who’s leaving Chicago with a skip in their step and who might be dragging their feet all the way home.


The whole CAR-T cohort. Bluebird Bio stoked hopes that CAR-T will be more than a one-trick cell therapy with promising early data in multiple myeloma. A virtually unknown Chinese entrant, vividly named Nanjing Legend Biotech, came through with intriguing results of its own. And even the beleaguered Juno Therapeutics had good news to report in the form of positive results in lymphoma. The read-through: Hot-wiring cells to fight cancer is difficult, but scientists are gradually wrapping their heads around the idea. CAR-T sentiment is nowhere near 2014’s hysteria, but it’s on the mend after hitting a nadir last summer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy